Please assess the completion status of the following clinical trial:

Trial Title: PTH and Vibration in OSteoporosis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women starting PTH treatment for osteoporosis according to Danish Osteoporosis guidelines~Exclusion Criteria:~* Women currently taking oral glucocorticoids~* Women unable to give informed consent~* Women unable to stand for 2 minutes at a time on the vibration platform~* Women who have contraindications to WBV (e.g. joint prosthesis, pacemakers)

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- controlgroup (Type: ACTIVE_COMPARATOR): Teriparatide, 20 microgram/day. 24 months of treatment
- studygroup 1 (Type: EXPERIMENTAL): Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms.
- studygroup 2 (Type: EXPERIMENTAL): Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms

Based on this trial design, predict the completion outcome and termination type (if applicable).